File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database

TitleTrans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database
Authors
KeywordsElderly patients
Hepatocellular carcinoma
Trans-arterial chemo-embolization
Issue Date2014
PublisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1
Citation
Liver International, 2014, v. 34 n. 7, p. 1109-1117 How to Cite?
AbstractOBJECTIVE: Hepatocellular carcinoma (HCC) incidence among elderly patients is increasing. Trans-arterial chemo-embolization (TACE) prolongs survival in selected HCC patients. The safety and efficacy of TACE in elderly patients has not been extensively studied. The objective of this study was to assess the safety and efficacy of TACE in elderly patients (older than 75) with HCC. DESIGN: Combined HCC registries (Spain, Italy, China and Israel) and cohort design analysis of patients who underwent TACE for HCC. RESULTS: Five hundred and forty-eight patients diagnosed and treated between 1988 and 2010 were included in the analysis (China 197, Italy 155, Israel 102 and Spain 94,). There were 120 patients (22%) older than 75 years and 47 patients (8.6%) older than 80. Median (95% CI) survival estimates were 23 (17-28), 21 (17-26) and 19 (15-23) months (P=0.14) among patients aged younger than 65, 65-75 and older than 75 respectively. An age above 75 years at diagnosis was not associated with worse prognosis, hazard ratio of 1.05 (95% CI 0.75-1.5), controlling for disease stage, sex, diagnosis year, HBV status and stratifying per database. No differences in complication rates were found between the age groups. CONCLUSIONS: TACE is safe for patients older than 75 years. Results were similar over different eras and geographical locations. Though selection bias is inherent, the results suggest overall adequate selection of patients, given the similar outcomes among the different age groups.
Persistent Identifierhttp://hdl.handle.net/10722/196578
ISSN
2019 Impact Factor: 5.175
2015 SCImago Journal Rankings: 1.677
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorCohen, MJ-
dc.contributor.authorLevy, I-
dc.contributor.authorBarak, O-
dc.contributor.authorBloom, AI-
dc.contributor.authorFernández-Ruiz, M-
dc.contributor.authorDi Maio, M-
dc.contributor.authorPerrone, F-
dc.contributor.authorPoon, RTP-
dc.contributor.authorShouval, D-
dc.contributor.authorYau, TCC-
dc.contributor.authorShibolet, O-
dc.date.accessioned2014-04-22T08:38:00Z-
dc.date.available2014-04-22T08:38:00Z-
dc.date.issued2014-
dc.identifier.citationLiver International, 2014, v. 34 n. 7, p. 1109-1117-
dc.identifier.issn1478-3223-
dc.identifier.urihttp://hdl.handle.net/10722/196578-
dc.description.abstractOBJECTIVE: Hepatocellular carcinoma (HCC) incidence among elderly patients is increasing. Trans-arterial chemo-embolization (TACE) prolongs survival in selected HCC patients. The safety and efficacy of TACE in elderly patients has not been extensively studied. The objective of this study was to assess the safety and efficacy of TACE in elderly patients (older than 75) with HCC. DESIGN: Combined HCC registries (Spain, Italy, China and Israel) and cohort design analysis of patients who underwent TACE for HCC. RESULTS: Five hundred and forty-eight patients diagnosed and treated between 1988 and 2010 were included in the analysis (China 197, Italy 155, Israel 102 and Spain 94,). There were 120 patients (22%) older than 75 years and 47 patients (8.6%) older than 80. Median (95% CI) survival estimates were 23 (17-28), 21 (17-26) and 19 (15-23) months (P=0.14) among patients aged younger than 65, 65-75 and older than 75 respectively. An age above 75 years at diagnosis was not associated with worse prognosis, hazard ratio of 1.05 (95% CI 0.75-1.5), controlling for disease stage, sex, diagnosis year, HBV status and stratifying per database. No differences in complication rates were found between the age groups. CONCLUSIONS: TACE is safe for patients older than 75 years. Results were similar over different eras and geographical locations. Though selection bias is inherent, the results suggest overall adequate selection of patients, given the similar outcomes among the different age groups.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1-
dc.relation.ispartofLiver International-
dc.subjectElderly patients-
dc.subjectHepatocellular carcinoma-
dc.subjectTrans-arterial chemo-embolization-
dc.titleTrans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database-
dc.typeArticle-
dc.identifier.emailPoon, RTP: poontp@hku.hk-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityPoon, RTP=rp00446-
dc.identifier.authorityYau, TCC=rp01466-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/liv.12486-
dc.identifier.pmid24512125-
dc.identifier.scopuseid_2-s2.0-84904464575-
dc.identifier.hkuros228562-
dc.identifier.volume34-
dc.identifier.issue7-
dc.identifier.spage1109-
dc.identifier.epage1117-
dc.identifier.isiWOS:000339723900037-
dc.publisher.placeUnited States-
dc.identifier.issnl1478-3223-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats